Continuing Metformin in Pregnancy Has Little Effect on Nonlive Birth

Medically reviewed by Carmen Pope, BPharm. Last updated on June 18, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, June 18, 2024 -- Continuing metformin and adding insulin in early pregnancy does not significantly alter the risk for nonlive birth or live birth with congenital malformations compared with switching to insulin monotherapy, according to a study published online June 18 in the Annals of Internal Medicine.

Yu-Han Chiu, M.D., Sc.D., from the Harvard T.H. Chan School of Public Health in Boston, and colleagues examined the teratogenicity of metformin use in the first trimester of pregnancy in an observational cohort study of 12,489 pregnant women with pregestational type 2 diabetes receiving metformin monotherapy before the last menstrual period (LMP). Two treatment strategies were assessed: insulin monotherapy (discontinue metformin and initiate insulin within 90 days of LMP; 850 women) and insulin plus metformin (continue metformin and initiate insulin within 90 days of LMP; 1,557 women).

The researchers found that the estimated risk for nonlive birth was 32.7 and 34.3 percent under insulin monotherapy and insulin plus metformin, respectively (risk ratio, 1.02; 95 percent confidence interval, 1.01 to 1.04). The estimated risk for live birth with congenital malformations was 8.0 and 5.7 percent under insulin monotherapy and insulin plus metformin, respectively (risk ratio, 0.72; 95 percent confidence interval, 0.51 to 1.09).

"Current recommendations of switching from metformin to insulin before pregnancy for the management of type 2 diabetes in pregnancy based on teratogenicity concerns may require reconsideration," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords